Show simple item record

dc.contributor.authorVander Heiden, Matthew G.
dc.contributor.authorLocasale, Jason W.
dc.contributor.authorSwanson, Kenneth D.
dc.contributor.authorSharfi, Hadar
dc.contributor.authorHeffron, Gregory J.
dc.contributor.authorAmador-Noguez, Daniel
dc.contributor.authorChristofk, Heather R.
dc.contributor.authorWagner, Gerhard
dc.contributor.authorRabinowitz, Joshua D.
dc.contributor.authorAsara, John M.
dc.contributor.authorCantley, Lewis C.
dc.date.accessioned2014-02-27T17:09:54Z
dc.date.available2014-02-27T17:09:54Z
dc.date.issued2010-09
dc.date.submitted2010-02
dc.identifier.issn0036-8075
dc.identifier.issn1095-9203
dc.identifier.urihttp://hdl.handle.net/1721.1/85108
dc.description.abstractProliferating cells, including cancer cells, require altered metabolism to efficiently incorporate nutrients such as glucose into biomass. The M2 isoform of pyruvate kinase (PKM2) promotes the metabolism of glucose by aerobic glycolysis and contributes to anabolic metabolism. Paradoxically, decreased pyruvate kinase enzyme activity accompanies the expression of PKM2 in rapidly dividing cancer cells and tissues. We demonstrate that phosphoenolpyruvate (PEP), the substrate for pyruvate kinase in cells, can act as a phosphate donor in mammalian cells because PEP participates in the phosphorylation of the glycolytic enzyme phosphoglycerate mutase (PGAM1) in PKM2-expressing cells. We used mass spectrometry to show that the phosphate from PEP is transferred to the catalytic histidine (His11) on human PGAM1. This reaction occurred at physiological concentrations of PEP and produced pyruvate in the absence of PKM2 activity. The presence of histidine-phosphorylated PGAM1 correlated with the expression of PKM2 in cancer cell lines and tumor tissues. Thus, decreased pyruvate kinase activity in PKM2-expressing cells allows PEP-dependent histidine phosphorylation of PGAM1 and may provide an alternate glycolytic pathway that decouples adenosine triphosphate production from PEP-mediated phosphotransfer, allowing for the high rate of glycolysis to support the anabolic metabolism observed in many proliferating cells.en_US
dc.description.sponsorshipDamon Runyon Cancer Research Foundationen_US
dc.description.sponsorshipBurroughs Wellcome Funden_US
dc.description.sponsorshipAmerican Cancer Societyen_US
dc.description.sponsorshipDana-Farber/Harvard Cancer Centeren_US
dc.description.sponsorshipNational Institutes of Health (U.S.) (NIH 1K08CA136983)en_US
dc.description.sponsorshipNational Institutes of Health (U.S.) (NIH 5P30CA006516-43)en_US
dc.description.sponsorshipNational Institutes of Health (U.S.) (NIH 5 T32 CA009361-28)en_US
dc.description.sponsorshipNational Institutes of Health (U.S.) (NIH R21/R33 DK070299)en_US
dc.description.sponsorshipNational Institutes of Health (U.S.) (NIH P01GM047467)en_US
dc.description.sponsorshipNational Institutes of Health (U.S.) (NIH R01 AI078063)en_US
dc.description.sponsorshipNational Institutes of Health (U.S.) (NIH R21 CA12862)en_US
dc.description.sponsorshipNational Institutes of Health (U.S.) (NIH R01-GM56302)en_US
dc.description.sponsorshipUnited States. Public Health Service (NIH P01CA089021)en_US
dc.description.sponsorshipNational Institutes of Health (U.S.) (NIH 1P01CA120964-01A)en_US
dc.language.isoen_US
dc.publisherAmerican Association for the Advancement of Scienceen_US
dc.relation.isversionofhttp://dx.doi.org/10.1126/science.1188015en_US
dc.rightsArticle is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.en_US
dc.sourcePMCen_US
dc.titleEvidence for an Alternative Glycolytic Pathway in Rapidly Proliferating Cellsen_US
dc.typeArticleen_US
dc.identifier.citationVander Heiden, Matthew G., Jason W. Locasale, Kenneth D. Swanson, Hadar Sharfi, Greg J. Heffron, Daniel Amador-Noguez, Heather R. Christofk, Gerhard Wagner, Joshua D. Rabinowitz, John M. Asara, and Lewis C. Cantley. "Evidence for an Alternative Glycolytic Pathway in Rapidly Proliferating Cells." Science 17 September 2010: 329 (5998), 1492-1499.en_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Biologyen_US
dc.contributor.departmentKoch Institute for Integrative Cancer Research at MITen_US
dc.contributor.mitauthorVander Heiden, Matthew G.en_US
dc.relation.journalScienceen_US
dc.eprint.versionAuthor's final manuscripten_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dspace.orderedauthorsVander Heiden, M. G.; Locasale, J. W.; Swanson, K. D.; Sharfi, H.; Heffron, G. J.; Amador-Noguez, D.; Christofk, H. R.; Wagner, G.; Rabinowitz, J. D.; Asara, J. M.; Cantley, L. C.en_US
dc.identifier.orcidhttps://orcid.org/0000-0002-6702-4192
mit.licensePUBLISHER_POLICYen_US
mit.metadata.statusComplete


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record